Renal Dosing of Antibiotics: Are We Jumping the Gun?

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Ryan L CrassManjunath P Pai

Abstract

Antibiotic renal dose adjustments are determined in patients with stable chronic kidney disease and may not translate to patients in late-phase trials and practice. Ceftolozane/tazobactam, ceftazidime/avibactam, and telavancin all carry precautionary statements for reduced clinical response in patients with baseline creatinine clearance of 30-50 mL/min, potentially due to unnecessary dose reduction in the setting of acute kidney injury (AKI). In this review, we discuss the regulatory landscape for antibiotics eliminated by the kidney and highlight the importance of the first 48 hours of therapy. Using a clinical database, we identified AKI on admission in a substantial proportion of patients with pneumonia (27.1%), intraabdominal (19.5%), urinary tract (20.0%), or skin and skin structure infections (9.7%) that resolved by 48 hours in 57.2% of cases. We suggest that deferred renal dose reduction of wide therapeutic index antibiotics could improve outcomes in patients with infectious diseases.

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Jun 1, 1985·Kidney International·S M Moran, B D Myers
Sep 25, 1971·Lancet·R W Jelliffe, S M Jelliffe
Dec 10, 1998·Journal of Internal Medicine·L LeiboviciS D Pitlik
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas P LodiseMichael J Rybak
Aug 16, 2006·Annals of Internal Medicine·Andrew S LeveyUNKNOWN Chronic Kidney Disease Epidemiology Collaboration
Dec 2, 2008·Critical Care : the Official Journal of the Critical Care Forum·A Mary VilayBruce A Mueller
Feb 27, 2009·Journal of the American Society of Nephrology : JASN·Sushrut S Waikar, Joseph V Bonventre
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
May 13, 2010·Critical Care : the Official Journal of the Critical Care Forum·Etienne MacedoUNKNOWN Program to Improve Care in Acute Renal Disease Study
Aug 25, 2010·Antimicrobial Agents and Chemotherapy·Mical PaulLeonard Leibovici
Feb 15, 2012·Clinical and Experimental Nephrology·Masatomo YashiroTadashi Kamata
May 25, 2013·Journal of the American Society of Nephrology : JASN·Sheldon Chen
Jun 3, 2014·Critical Care : the Official Journal of the Critical Care Forum·Marjorie BeumierFabio Silvio Taccone
Oct 19, 2014·Journal of Intensive Care Medicine·Susan J Lewis, Bruce A Mueller
Feb 12, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph SolomkinChristian Eckmann
Sep 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Melinda K LacySteven L Barriere
Mar 6, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Evan J ZasowskiMichael J Rybak
Mar 11, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John E MazuskiJan Pachl
Feb 28, 2017·Nature Reviews. Nephrology·Lakhmir S ChawlaUNKNOWN Acute Disease Quality Initiative Workgroup 16.
May 27, 2017·Critical Care : the Official Journal of the Critical Care Forum·Ching-Chi LeeWen-Chien Ko
Dec 19, 2017·Journal of Clinical Pharmacology·Randall K HooverSue K Cammarata
Jan 10, 2018·Antimicrobial Agents and Chemotherapy·Christopher M RubinoDavid C Griffith
Mar 15, 2018·Journal of Clinical Pharmacology·Randall HooverSue K Cammarata

❮ Previous
Next ❯

Citations

Oct 1, 2019·Current Opinion in Infectious Diseases·Christian M Gill, David P Nicolau
Nov 26, 2019·The Annals of Pharmacotherapy·Alison K LewGregory Eschenauer
Jun 18, 2020·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Rodrigo P Dos SantosJosé Miguel Dora
Sep 17, 2020·Journal of Pharmacy Practice·Joshua A HendricksonPatrick M McDaneld
Sep 9, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas J DilworthWarren E Rose
Aug 3, 2020·Current Opinion in Critical Care·Adrian John Brink, Guy Richards
Jan 4, 2020·Anaesthesia Critical Care & Pain Medicine·Ryan L CrassJason A Roberts
Jan 22, 2021·Journal of Veterinary Internal Medicine·Kelly N MonaghanMark G Papich
Dec 9, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Suzanne L de VroomSuzanne E Geerlings
Dec 22, 2020·Frontiers in Medicine·Dagan O LonsdaleJeffrey Lipman
Dec 15, 2020·International Journal of Nephrology·Jonathan S Chávez-IñiguezGuillermo García-García
Jan 9, 2021·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Milo GattiFabrizio De Ponti
Feb 2, 2021·Clinical Pharmacology and Therapeutics·Manjunath P Pai
Feb 12, 2021·Clinical Pharmacology and Therapeutics·Cornelia B Landersdorfer, Roger L Nation
Mar 19, 2021·Expert Opinion on Drug Metabolism & Toxicology·Marco FioreMaya Hites
May 4, 2021·Seminars in Dialysis·Soo Min Jang, Linda Awdishu
Feb 23, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mario TumbarelloPierluigi Viale
Apr 21, 2021·Antimicrobial Agents and Chemotherapy·Bryan D LizzaMarin H Kollef
Jun 23, 2021·International Journal of Antimicrobial Agents·Elio CastagnolaFrancesca Mattioli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinical Journal of the American Society of Nephrology : CJASN
John W PickeringZoltán H Endre
Nihon rinsho. Japanese journal of clinical medicine
Yasuhiko Iino
Nefrología : publicación oficial de la Sociedad Española Nefrologia
Fernando Caravaca-FontánCarlos Quereda Rodríguez-Navarro
© 2022 Meta ULC. All rights reserved